Results 171 to 180 of about 72,150 (302)

Hematopoietic effects of tagraxofusp in treatment‐naive patients with blastic plasmacytoid dendritic cell neoplasm

Cancer, Volume 132, Issue 1, 1 January 2026.
Abstract Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic neoplasm that expresses CD123, is often observed in the bone marrow (BM), as well as skin, blood, and viscera. Tagraxofusp, a first‐in‐class CD123‐targeted therapy, is the only drug approved to treat BPDCN.
Marina Konopleva, Naveen Pemmaraju, Kendra L. Sweet, Anthony S. Stein, David A. Rizzieri, Eunice S. Wang, Sumithira Vasu, Todd Rosenblat, Michael Zuurman, Ira Gupta, Andrew A. Lane   +10 more
wiley   +1 more source

Recurrent cytarabine-induced sinus bradycardia in a patient with acute myeloid leukemia: a case report and review of the literature. [PDF]

J Med Case Rep
Tesfaye T, Mamo EW, Assefa D, Barega B, Seleshi T, Goshu DY.   +5 more
europepmc   +1 more source

Fludarabine and cytarabine is not superior to high dose cytarabine as consolidation therapy in standard risk AML in children: Results from the international Phase III MyeChild01 trial [PDF]

Brenda Gibson, André Baruchel, Andrew S. Moore, Shanna Maycock, Owen Smith, Geoff Shenton, C. Rénard, Nicholas Heaney, Anna Lawson, Persis Amrolia, Paul Saultier, Marc Ansari, Hélène Lapillonne, Richard Dillon, Jelena Jovanović, Siobhan Cross, Paul Virgo, Lucy Wheeler, Christophe Roumier, Nicolas Duployez, Christine J. Harrison, Claire Schwab, Wendy Cuccuini, Mårina Lafage‐Pochitaloff, Claude Preudhomme, Pierre Hirsch, Gareth J. Veal, David C. Gillis, Pamela Kearns, G Leverger, Philip Ancliff, Aimee Jackson, Arnaud Petit   +32 more
openalex   +1 more source

Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracycline Toxicity [PDF]

, 2011
Edward Agura, Barry Cooper, Houston Holmes, Estil Vance, R.B. Berryman, Christopher Maisel, Sandy Li, Giovanna Saracino, Mirjana Tadic-Ovcina, Joseph W. Fay   +9 more
openalex   +1 more source

Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety

Cancer Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background Dasatinib, a potent second‐generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML‐CP) resistant to imatinib at standard dosing (100 mg daily), but is often limited by adverse events.
Nandhini Gangadaran, Harshal Mamlekar, Souvik Saha, Rajesh Kashyap, Sanjeev Yadav, Khaliqur Rahman, Ruchi Gupta, Mona Vijayaran, Manish Singh, Dinesh Chandra   +9 more
wiley   +1 more source

Corneal epithelial microcysts due to high dose Cytarabine administration in acute myeloid leukemia

Turkish Journal of Hematology, 2012
Tuba Hilkay Karapınar, Salih Gözmen, Özlem Tüfekçi, Şebnem Yılmaz, Zeynep Özbek, Melih Parlak, Gülersu İrken, Hale Ören   +7 more
doaj   +1 more source

Blinatumomab in de novo AYA ALL—Results of the Australasian Leukaemia and Lymphoma Group ALL09 “SUBLIME” study

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Pediatric regimens improve outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients. End‐consolidation (time point 2 [TP2]) minimal residual disease negativity (MRDneg) is associated with improved survival. In this study, standard consolidation chemotherapy was replaced with blinatumomab to improve TP2 MRDneg—a ...
Matthew Greenwood, Shane Gangatharan, Michael Osborn, Ashley P. Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Jacqueline Rehn, Elyse Page, Susan Heatley, Peter Button, Leesa Rowley, Stephen R. Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla Pozza, David Yeung, Deborah White, the Australasian Leukaemia and Lymphoma Group   +26 more
wiley   +1 more source

Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapies have revolutionized the treatment of hematological malignancies, achieving high response rates in patients with relapsed or refractory disease. Despite these benefits, CAR‐T cell therapies are associated with unique toxicities, including cytokine release syndrome (CRS), immune effector cell ...
Livia Donzelli, Veronica Zullino, Giovanni Fernando Torelli, Maria Stefania De Propris, Mario Piazzolla, Franco Ruberto, Maurizio Martelli, Alice Di Rocco   +7 more
wiley   +1 more source

Portraits of clonal hematopoiesis in DNMT3A/TET2/ASXL1-mutant myelodysplastic neoplasms and acute myeloid leukemia. [PDF]

Ann Hematol
Patel SA, Khedr S, Hutchinson L, Xie Y, Khouri MR, Cerny J, Gerber JM.   +6 more
europepmc   +1 more source

The effect of cephalexin in influencing the pharmacokinetics of a novel drug – 5′-valyl-cytarabine hydrochloride

, 2016
Xiaotong Song, Yinghua Sun, Chenyao Zhao, Zhonggui He   +3 more
openalex   +1 more source